Chemosensitizing potential of PL
| Drugs | Cancer | In vitro/In vivo | Model | Mechanism | References |
|---|---|---|---|---|---|
| Bortezomib | MM | In vitro | NCI-H929 | ↑Apoptosis, ↓p-STAT3 | [110] |
| Cisplatin | HNC | In vitro | AMC-HN2, -HN3, -HN4, -HN6, -HN7, -HN8, SNU-1041, -1066, -1076, HN30, HN31, UMSCC1, 93-VU-147T | ↑ROS, ↓GSH, ↑GSSG, ↑PUMA, ↑cleaved PARP, ↑p-JNK, ↓GSTP1, -HN9, ↑p-p53 (Ser 15), ↑apoptosis | [149] |
| In vivo | AMC-HN2 & -HN9, xenograft | ↓Tumor growth, ↑p53, ↑apoptosis | [149] | ||
| Doxorubicin | Prostate cancer | In vitro | DU-145 | ↑Apoptosis, ↑caspase-3, ↑cleaved PARP | [148] |
| 5-Flurouracil | Oral cancer | In vitro | SAS, CGHNC8 | ↓Cell viability, ↓survival | [144] |
| Gemcitabine | Pancreatic cancer | In vitro | BxPC-3, PANC-1, AsPC-1 | ↑Apoptosis, ↓NF-κB | [115] |
| In vivo | BxPC-3 xenograft | ↓Tumor burden, ↑apoptosis, ↓NF-κB | [115] | ||
| Oxaliplatin | Gastric cancer | In vitro | SGC-7901, AGS, BGC-823 | ↓TrxR1 activity, ↑ROS, ↑apoptosis, Activation of p38 and JNK signaling pathways, ↑γ-H2A.X | [147] |
| In vivo | SGC-7901 xenograft | ↓Tumor growth, ↓TrxR1 activity | [147] | ||
| PTX | Intestinal Cancer | In vitro | INT-407 and HCT-116 | ↓Proliferation | [127] |
GSSG: GSH disulphide; p: phosphorylated